17th May 2021 16:00
Hikma Pharmaceuticals PLC - EIP B and EIP C Vesting
LONDON, 17 May 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 17 May 2019 under the 2014 Executive Incentive Plan ("EIP") Element B and granted on 16 May 2018 under the 2014 EIP Element C. The Element B awards vested two years after grant and the Element C awards vested three years after grant.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Mazen Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Vice Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on16 May 2021 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 12,042 |
d) | Aggregated information - Volume - Price
Total |
12,042 £0.00 £0.00 |
e) | Date of the transaction | 17 May 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Riad Mishlawi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on16 May 2021 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 22,601 |
d) | Aggregated information - Volume - Price
- Total |
22,601 £0.00 £0.00 |
e) | Date of the transaction | 17 May 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Majda Labadi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Majda Labadi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on16 May 2021 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 15,855 |
d) | Aggregated information - Volume - Price
- Total |
15,855 £0.00 £0.00 |
e) | Date of the transaction | 17 May 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Bassam Kanaan |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on16 May 2021 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 25,729 |
d) | Aggregated information - Volume - Price
- Total |
25,729 £0.00 £0.00 |
e) | Date of the transaction | 17 May 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Khalid Nabilsi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on16 May 2021 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 23,062 |
d) | Aggregated information - Volume - Price
- Total |
23,062 £0.00 £0.00 |
e) | Date of the transaction | 17 May 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Susan Ringdal |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on16 May 2021 under the EIP Element C. Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 7,522
Price(s): £23.835 Volume(s): 6,735 |
d) | Aggregated information - Volume - Price
- Total |
14,257 £23.835 £160,528.73p |
e) | Date of the transaction | 17 May 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Hussein Arkhagha
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Hussein Arkhagha |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 May 2021 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 11,246 |
d) | Aggregated information - Volume - Price
- Total |
11,246 £0.00 £0.00 |
e) | Date of the transaction | 17 May 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760
17 May 2021
Related Shares:
Hikma Pharmaceuticals